Cogent Biosciences Inc. (COGT)
NASDAQ: COGT
· Real-Time Price · USD
5.13
0.32 (6.65%)
At close: May 12, 2025, 3:59 PM
5.05
-1.46%
After-hours: May 12, 2025, 06:40 PM EDT
6.65% (1D)
| Bid | 4.6 |
| Market Cap | 583.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -255.86M |
| EPS (ttm) | -1.97 |
| PE Ratio (ttm) | -2.6 |
| Forward PE | -2.59 |
| Analyst | Buy |
| Ask | 5.99 |
| Volume | 631,048 |
| Avg. Volume (20D) | 1,338,406 |
| Open | 5.17 |
| Previous Close | 4.81 |
| Day's Range | 5.08 - 5.30 |
| 52-Week Range | 3.72 - 12.61 |
| Beta | 0.22 |
About COGT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol COGT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for COGT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
-15.84%
Cogent Biosciences shares are trading lower after ...
Unlock content with
Pro Subscription
11 months ago
-6.12%
Cogent Biosciences shares are trading lower. The company announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis.
